Global Information
회사소개 | 문의 | 비교리스트

세계의 오피오이드 사용장애 시장(2019-2025년)

Opioid Use Disorder Market 2019-2025

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949573
페이지 정보 영문
가격
US $ 3,600 ₩ 4,243,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,658,000 Printable PDF (Enterprise License)


세계의 오피오이드 사용장애 시장(2019-2025년) Opioid Use Disorder Market 2019-2025
발행일 : 2020년 06월 페이지 정보 : 영문

세계 오피오이드 사용장애 시장은 예측기간 중 주목할 만한 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 오피오이드의 높은 부작용과 OUD 환자 증가는 세계 오피오이드 시장 성장을 촉진하고 있는 주요인입니다. 미국 정신의학회에 의하면, 2017년 미국에서는 오피오이드 과잉섭취에 의해 3만 1,000명 이상이 사망했고, 그 중 1만 6,000명 이상이 헤로인 과잉섭취에 의해 사망했으며, 1만 5,000명이 처방 오피오이드 과잉섭취에 의해 사망했습니다. 카운셀링, 오피오이드 보충 요법, 점진적인 오피오이드 중지는 OUD를 방지하기 위해서 사용되는 비약물 요법 일부입니다.

북미에서는 약물 오용이나 사람들의 의식에 대한 정부 정책에 의해 높은 점유율을 볼 수 있었습니다. 예를 들어, 2017년 10월 미국에서는 질병관리예방센터(CDC)가 Rx 인식 캠페인을 시작하고, 오피오이드 과잉섭취에 의한 부작용에 대해 국민에게 알렸습니다.

세계의 오피오이드 사용장애(Opioid Use Disorder) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 치료별·지역별 시장 규모 추이와 예측, 경쟁 구도, 주요 기업 개요, 시장 기회 등의 정보를 전해드립니다.

목차

제1장 보고서 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트 인사이트와 현재 시장 동향

제3장 경쟁 구도

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • Alkermes, PLC
    • BioDelivery Sciences International, Inc.
    • Titan Pharmaceuticals, Inc.
    • Orexo US, Inc.
    • Hikma Pharmaceuticals PLC

제4장 시장 영향요인

  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회

제5장 세계의 오피오이드 사용장애 시장 세분화

  • 치료별
    • Methadone
    • Buprenorphine
    • Naltrexone

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 기타 지역

제7장 기업 개요

  • Alkermes, PLC.
  • BioDelivery Sciences International, Inc.
  • Camurus AB
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Mallinckrodt Co.
  • Masimo Corp.
  • MediciNova, Inc.
  • Mylan N.V.
  • Novartis AG
  • Omeros Corp.
  • Orexo US, Inc.
  • Teva Pharmaceuticals Industrial, Ltd.
  • Titan Pharmaceuticals, Inc.
LSH 20.08.11

LIST OF TABLES

  • 1. GLOBAL OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY DRUG, 2018-2025 ($ MILLION)

2. GLOBAL METHADONE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)

  • 3. GLOBAL BUPRENORPHINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL BUNAVIL (BUPRENORPHINE) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL SUBOXONE (BUPRENORPHINE) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL ZUBSCLV (BUPRENORPHINE) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL SUBLOCADE (BUPRENORPHINE) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL OTHERS (BUPRENORPHINE) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL NALTREXONE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 10. GLOBAL OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 11. NORTH AMERICAN OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 13. EUROPEAN OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 14. EUROPEAN OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 15. ASIA-PACIFIC OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 16. ASIA-PACIFIC OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 17. REST OF THE WORLD OPIOID USE DISORDER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL OPIOID USE DISORDER MARKET SHARE BY DRUG, 2018 VS 2025 (%)
  • 2. GLOBAL OPIOID USE DISORDER MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD OPIOID USE DISORDER MARKET SIZE, 2018-2025 ($ MILLION)

Global Opioid Use Disorder Market Size, Share & Trends Analysis Report, by Drug (Methadone, Buprenorphine {Bunavil, Suboxone, Zubsclv, Buprenorphine} Naltrexone) and Forecast 2019-2025

The global opioid use disordermarket is estimated to grow at a significant CAGRduring the forecast period.High side effects of opioids and the rising frequency of OUD patients are the major factors that are driving the global opioid market.As per the American Psychiatric Association, In 2017, in the US, over 31,000 people died from an opioid overdose, both prescribed and non-prescribed, among them over 16,000 people died from the overdose of heroin and 15,000 people died from the overdose of prescribes opioids. Counseling, opioid replacement therapy, and gradual discontinuation of opioids are some of the non-medication therapies that are used to prevent OUD.

The global opioid use disordermarket is segmented based on Drug type. Based on drug type, the market is segmented into Methadone, Buprenorphine, and Naltrexone. And Buprenorphine is segmented into Bunavil, Suboxone, Zubsclv, Sublocade, and Others.Based on geography, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and RoW. North America has witnessed significant share owing to the availability of government policies for the misuse of drugs and awareness among people. For instance, in October 2017, in the US, in the Center for Disease Control and Prevention (CDC) launched the Rx Awareness campaign, to aware the public about side effects of the overdose of opioids.

The major players providing opioid use disorder (OUD) drugs include Indivior PLC, BioDelivery Sciences International, Inc., Alkermes, PLC, Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corp, Camurus AB, Hikma Pharmaceuticals PLC, and others. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance, in November 2017, Alkermes, Inc. launched OUD drug VIVITROL, it was funded by the National Institute on Drug Abuse (NIDA), and it is the injectable and only once-monthly formulation.

Research Methodology

The market study of the global opioid use disorder market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The report is intended for providers, suppliers, and distributors of an opioid use disorder, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

Market Segmentation-

  • Global Opioid Use Disorder Market Research and Analysis by Drug Type

The Report Covers:

  • Comprehensive research methodology of the global opioid use disorder market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global opioid use disorder market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusions

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Alkermes, PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. BioDelivery Sciences International, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Titan Pharmaceuticals, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Orexo US, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Hikma Pharmaceuticals PLC
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Global Opioid Use Disorder Market by Segmentation

  • 5.1. By Treatment
    • 5.1.1. Methadone
    • 5.1.2. Buprenorphine
      • 5.1.2.1. Bunavil
      • 5.1.2.2. Suboxone
      • 5.1.2.3. Zubsclv
      • 5.1.2.4. Sublocade
      • 5.1.2.5. Others
    • 5.1.3. Naltrexone

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Alkermes, PLC.
  • 7.2. BioDelivery Sciences International, Inc.
  • 7.3. Camurus AB
  • 7.4. Hikma Pharmaceuticals PLC
  • 7.5. Indivior PLC
  • 7.6. Mallinckrodt Co.
  • 7.7. Masimo Corp.
  • 7.8. MediciNova, Inc.
  • 7.9. Mylan N.V.
  • 7.10. Novartis AG
  • 7.11. Omeros Corp.
  • 7.12. Orexo US, Inc.
  • 7.13. Teva Pharmaceuticals Industrial, Ltd.
  • 7.14. Titan Pharmaceuticals, Inc.
Back to Top
전화 문의
F A Q